Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

Journal of Cardiovascular Pharmacology
Yejia SongLuiz Belardinelli

Abstract

The new anti-anginal drug ranolazine causes a slight (<10 milliseconds) prolongation of the QT interval, raising the concern that its use may be associated with an increased incidence of torsades de pointes ventricular tachyarrhythmias. The goal of this study was to show that ranolazine inhibits the late component of INa and attenuates prolongation of action potential duration when late INa is increased, both in the absence and presence of IK-blocking drugs. Currents and action potentials of guinea pig isolated ventricular myocytes were measured by whole-cell patch clamp. Sea anemone toxin (ATX)-II was used to increase late INa and mimic the effect of an SCN5A gene mutation. ATX-II (3-5 nmol/L) increased late INa by 5-fold; ranolazine attenuated this increase of late INa by up to 61 +/- 8%. ATX-II (10-20 nmol/L) increased action potential duration (APD) by > 1 seconds, and caused early afterdepolarizations; both actions were attenuated by ranolazine (0.1-30 micromol/L). Ranolazine (10 micromol/L) reduced by 89% the 13.6-fold increase in variability of APD caused by 10 nmol/L ATX-II. The effects of ATX-II (3 nmol/L) in combinations with either the IKr blocker E-4031 or the IKs blocker chromanol 293B to increase APD were attenuat...Continue Reading

References

Jul 23, 1987·Biochimica Et Biophysica Acta·W SchreibmayerH A Tritthart
Aug 24, 1995·Nature·P B BennettA L George
May 30, 1998·Pacing and Clinical Electrophysiology : PACE·D M Roden
Mar 23, 1999·Circulation·W Shimizu, C Antzelevitch
May 6, 1999·Cellular and Molecular Life Sciences : CMLS·A I UndrovinasH N Sabbah
Sep 2, 2000·Journal of Cardiovascular Electrophysiology·D M Roden
Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·J S MitchesonM C Sanguinetti
Mar 10, 2001·Journal of Cardiovascular Electrophysiology·B HuangN El-Sherif
Jan 16, 2002·Current Opinion in Cardiology·Robert Dumaine, Charles Antzelevitch
Jan 24, 2002·Nature·Eduardo Marbán
Aug 24, 2002·Circulation Research·Margaret P ChandlerHani N Sabbah
Aug 24, 2002·Science·Igor SplawskiMark T Keating
Sep 5, 2002·Circulation·Naomasa MakitaAkira Kitabatake
Jan 23, 2003·Circulation·Mark T GladwinRichard O Cannon
Dec 5, 2003·Trends in Pharmacological Sciences·Luiz BelardinelliMarc A Vos
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators

❮ Previous
Next ❯

Citations

Nov 30, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·G Hasenfuss, L S Maier
Dec 19, 2012·Cardiovascular Drugs and Therapy·Neil J Wimmer, Peter H Stone
Jan 8, 2013·Cardiovascular Drugs and Therapy·Carol Ann Remme, Arthur A M Wilde
Jul 7, 2012·Current Heart Failure Reports·Lars S Maier
Jun 12, 2013·Cardiovascular Research·John C ShryockLuiz Belardinelli
Jun 14, 2005·Cardiology in Review·Joe R Anderson, James J Nawarskas
Sep 30, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Sharad RastogiHani N Sabbah
Jan 1, 2008·Circulation. Arrhythmia and Electrophysiology·Arthur J Moss, Ilan Goldenberg
Apr 28, 2006·Clinical Pharmacokinetics·Markus Jerling
Apr 16, 2014·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·H E DriessenM A Vos
Sep 8, 2011·Canadian Journal of Physiology and Pharmacology·Kirstine CalloeCharles Antzelevitch
Mar 4, 2014·Indian Heart Journal·Aditi VaishnavYash Lokhandwala
Jun 27, 2013·The Journal of Physiology·Zhuo FuZhenqi Liu
Mar 17, 2015·The Journal of Physiology·Colleen E ClancyAntonio Zaza
Apr 2, 2015·International Journal of Cardiology·Tanush GuptaSei Iwai
Nov 15, 2012·Archives of Medical Research·Ma Cristina Paredes-CarbajalDieter Mascher
Oct 10, 2012·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Gerrit FrommeyerPeter Milberg
Feb 23, 2012·Journal of Molecular and Cellular Cardiology·Malin K B JonssonToon A B van Veen
Dec 3, 2011·Pharmacology & Therapeutics·Samuel Sossalla, Lars S Maier
Jul 12, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mohammed AldakkakDavid F Stowe
Mar 23, 2011·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Charles AntzelevitchLuiz Belardinelli
Jul 14, 2010·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Gudrun Antoons, Morten B Thomsen
Sep 12, 2009·Journal of Molecular and Cellular Cardiology·Daniel M JohnsonPaul G A Volders
Dec 20, 2015·BMC Health Services Research·Georgia KourlabaNikos Maniadakis
Jul 30, 2008·Pharmacology & Therapeutics·Antonio ZazaJohn C Shryock
May 9, 2008·Journal of Molecular and Cellular Cardiology·Sharon L HaleRobert A Kloner
Jan 19, 2008·Journal of Molecular and Cellular Cardiology·David R Van Wagoner
May 1, 2007·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Serge SicouriCharles Antzelevitch
Mar 8, 2006·British Journal of Pharmacology·Sandra FredjRobert S Kass
Mar 8, 2006·British Journal of Pharmacology·Jonathan C Makielski, Carmen R Valdivia
Dec 12, 2007·British Journal of Pharmacology·J C Shryock, L Belardinelli
Jan 13, 2009·British Journal of Pharmacology·B VacherB Le Grand
May 12, 2006·Journal of Cardiovascular Electrophysiology·Charles Antzelevitch, Luiz Belardinelli
May 12, 2006·Journal of Cardiovascular Electrophysiology·Edward Carmeliet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.